Sofosbuvir and Oxaliplatin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sofosbuvir (sofosbuvir) and Oxaliplatin (oxaliplatin). Common drug interactions include anaemia among females and hepatitis c among males.

The phase IV clinical study analyzes what interactions people have when they take Sofosbuvir and Oxaliplatin. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Sofosbuvir?

Sofosbuvir has active ingredients of sofosbuvir. eHealthMe is studying from 9,194 Sofosbuvir users. Check the latest studies of Sofosbuvir.

What is Oxaliplatin?

Oxaliplatin has active ingredients of oxaliplatin. It is often used in colon cancer. eHealthMe is studying from 72,058 Oxaliplatin users. Check the latest studies of Oxaliplatin.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 23, 2026

22 people who take Sofosbuvir and Oxaliplatin together, and have interactions are studied.

Sofosbuvir and Oxaliplatin drug interactions.

What are the common drug interactions of Sofosbuvir and Oxaliplatin, by gender? *:

female:

Anaemia (lack of blood)
Diffuse large b-cell lymphoma (cancer of b cells, a type of white blood cell)
Left ventricular failure (left ventricle fails to contract forcefully)
Neutropenia (an abnormally low number of neutrophils)
Drug ineffective

male:

Hepatitis c
Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
Hepatotoxicity (chemical-driven liver damage)
Alanine aminotransferase increased

What are the common drug interactions of Sofosbuvir and Oxaliplatin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Diffuse large b-cell lymphoma (cancer of b cells, a type of white blood cell)
Left ventricular failure (left ventricle fails to contract forcefully)
Neutropenia (an abnormally low number of neutrophils)
Anaemia (lack of blood)

50-59:

n/a

60+:

Hepatitis c
Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
Hepatotoxicity (chemical-driven liver damage)
Alanine aminotransferase increased
Death
Drug ineffective
Nausea (feeling of having an urge to vomit)
Salivary hypersecretion (excess saliva secretion)
Vomiting

What are the existing conditions these people have? *

Hepatitis C: 17 people, 77.27%
Diffuse Large B-Cell Lymphoma Stage Iii (cancer of b cells, a type of white blood cell-stage iii): 12 people, 54.55%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 7 people, 31.82%
Diffuse Large B-Cell Lymphoma Stage Iv (cancer of b cells, a type of white blood cell-stage iv): 3 people, 13.64%

* Approximation only. Some reports may have incomplete information.

Do you take Sofosbuvir and Oxaliplatin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously